ArticleBlood advances2025
PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation.
Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- GvHD prophylaxis in elderly patients: post-transplant cyclophosphamide or ATG? A study by the EBMT transplant complications working party.Bone marrow transplantation · 2026Article
- PTCy-Based versus ATG-Based GVHD Prophylaxis in Mismatched Unrelated Donor HCT: A Secondary Analysis of CIBMTR Data.Transplantation and cellular therapy · 2026Article
- GVHD prophylaxis with PTCy, ATG, PTCy+ATG, or no in vivo T-cell depletion in RIC matched-donor PBSC transplantation for AML and MDS.Bone marrow transplantation · 2026Article
- Outcomes After Matched Sibling Donor Versus Haploidentical Hematopoietic Stem Cell Transplantation With Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis.Transplantation and cellular therapy · 2026Article
- Expanding the donor pool in secondary AML: a step forward, with caveats.Bone marrow transplantation · 2026Article
- Chronic graft-<I>versus</i>-host disease in the era of posttransplant cyclophosphamide.Haematologica · 2026Article
- Haploidentical transplantation with post-transplant cyclophosphamide is not inferior to 9/10-MUD transplantation with ATG in patients with myeloid malignancies.Bone marrow transplantation · 2026Article
- Impact of Dyslipidemia on Allogeneic Transplantation Outcomes and Cardiovascular Mortality in Patients with Acute Leukemias in the Post-Transplant Cyclophosphamide Era.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Impact of graft-versus-host disease prophylaxis strategies on GvHD-free/relapse-free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score-matched analysis.British journal of haematology · 2026Article
- Advances in graft-versus-host disease: emerging therapeutic strategies, biomarker discoveries, and innovative treatment approaches.Frontiers in immunology · 2026Review
- Haploidentical Allogeneic Cell Transplantation in Relapsed/Refractory Multiple Myeloma.Cancer management and research · 2026Article
- Epcoritamab as bridging therapy to successful second allogeneic HSCT in relapsed DLBCL after UCBT and CAR T cell therapy.International journal of hematology · 2026Article
- Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party.Bone marrow transplantation · 2025Article
- Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes.British journal of haematology · 2025Article
- Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCRαβ/CD19 depletion or post-transplant cyclophosphamide.British journal of haematology · 2025Article
- Article
- PTCy unchained in matched siblings: the D is silent in GVHD.Blood advances · 2025Article
- Short-course blinatumomab as a bridge-to-transplantation improves the survival of Ph-negative MRD-positive B-ALL.Cell transplantationArticle
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractPosttransplant cyclophosphamide (PTCy) is a promising graft-versus-host disease (GVHD) prophylaxis in haploidentical and matched unrelated donor hematopoietic stem cell transplantation (HSCT), but its role in matched sibling donor (MSD) transplants remains unclear. We conducted a retrospective study of 413 MSD-HSCT patients receiving peripheral blood stem cell (PBSC) grafts from January 2010 to January 2023. Patients were categorized into 4 groups: group I (calcineurin inhibitor [CNI] + methotrexate [MTX] or mycophenolate mofetil [MMF]), group II (CNI + MTX or MMF + antithymocyte globulin [ATG]), group III (PTCy + ATG + CNI), and group IV (PTCy + CNI + MMF). PTCy was associated with a significant reduction in grade 2- 4 and grade 3-4 acute GVHD and moderate-to-severe chronic GVHD compared with CNI + MTX (or MMF)-containing regimens. PTCy did not increase relapse risk; PTCy reduced nonrelapse mortality, leading to improved GVHD-free/relapse-free survival (GRFS; Hazard Ratio, 0.4; P < .001). PTCy was also associated with improved overall survival. Bloodstream infections were increased with PTCy. The addition of ATG to PTCy did not further improve GRFS and was associated with a higher incidence of clinically significant cytomegalovirus (csCMV) and Epstein-Barr virus (csEBV) reactivation and a numerical increase in NRM. PTCy significantly appeared to improve GRFS in the MSD setting using PBSC grafts. The addition of ATG to PTCy increases csCMV and csEBV reactivation without further improving GRFS. Prospective trials and PTCy dose optimization are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.